Methods and compositions relating to mek5 and cardiac hypertrophy and dilated cardiomyopathy
CA 2384907 A1 · Owner: Nicol, Rebekka · Inventors: Nicol, Rebekka; Olson, Eric N.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compositions and methods relating to MEK5 and its role, in heart disease. This protein has now been identified as a target for therapeutic intervention due, to its role molecular events that lead to or contribute to cardiac hypertrophy and/or dilated, cardiomyopathy. In particular inhibition of MEK5 activity will lead to decrease signalling of, the pathways and reduce or eliminate the effects on sarcomere assembly which , in turn result or, contribute to cardiac dysfunction. Also provided are transgenic animals and methods of, screening for inhibitors of MEK5.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 29, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.